* Caliper Technologies Corp., of Palo Alto, Calif., was awarded a $2 million contract from the Advanced Technology Program of the National Institute of Standards and Technology in the "Tools for DNA Diagnostics" competition. The goal of the project is development of a high-throughput DNA diagnostic platform based on Caliper's "lab-on-a-chip" technology.* Centocor Inc., of Malvern, Pa., launched Remicade (infliximab) for treatment of Crohn's disease. The drug was approved in August for patients with fistulizing Crohn's disease for reduction in the number of draining enterocutaneous fistulae. (See BioWorld Today, Aug. 25, 1998, p. 1.)
* Orchid Biocomputer Inc., of Princeton, N.J., began a $3 million program to develop a more affordable, flexible and powerful microfluidics chip for detecting polymorphic variations in DNA. Orchid's goal is to develop its high-throughput platform technologies for pharmacogenomics based on single nucleotide polymorphisms, believed to have an effect on the body's drug metabolism and response.
* Tripos Inc., of St. Louis, released GeneFold, a protein fold identification software tool. It is the first product launched in a two-year collaboration between Tripos and The Scripps Research Institute, of La Jolla, Calif. GeneFold identifies protein folds, or structures, that a given sequence is likely to fit.